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Context. Approximately 1.4–2% of all cases of acute pancreatitis are drug related in general population. The literature on statin-
induced pancreatitis consists primarily of anecdotal case reports. We report a case of possible rosuvastatin-induced pancreatitis.
Case Report. A 67-year-old female presented with progressively worsening abdominal pain and vomiting for 7 days. Home
medications included rosuvastatin and clonidine. CT scan of abdomen, with intravenous contrast, showed ﬁndings consistent
with acute pancreatitis. She responded to conservative management. Rosuvastatin was resumed at the time of discharge from the
hospital, and she presented two months later with recurrence of acute pancreatitis. Further workup ruled out all likely causes of
acutepancreatitis.Rosuvastatinwasstoppedcompletelywhenshewasdischargedthesecondtime,andshedidnothaveanyfurther
episodes of acute pancreatitis. She was completely asymptomatic throughout the 18-month follow-up period. Conclusion. This
paper reinforces the possible association of rosuvastatin, a novel statin, with acute pancreatitis, even though the exact underlying
mechanism of statin-induced pancreatitis remains unknown.
1.Introduction
Several causes of acute pancreatitis (AP) have been estab-
lished, but the most common are gallstones (30–60%) and
alcohol abuse (15–30%) [1]. Other common causes of
APincludehypertriglyceridemia,hyperparathyroidism,end-
oscopic retrograde cholangiopancreatography (ERCP), trau-
ma, pancreatic tumors, and surgery (intraabdominal and
nonabdominal) [2]. Drugs are a relatively uncommon cause
ofAPandaccountfor1.4–2%ofthecasesinthegeneralpop-
ulation [3]. Although anecdotal case reports have claimed
that statins cause AP, the exact incidence and mechanism of
this occurrence is unknown. We report a case of 67-year-
old female who developed AP during treatment with ro-
suvastatin; that was resolved upon discontinuation of the
drug, and it recurred after readministration of rosuvastatin
while other likely causes of AP were ruled out.
2.CaseReport
A 67-year-old female with a past medical history of hyper-
tension and dyslipidemia presented with nausea, vomiting,
and epigastric pain for 7 days. She admitted to a history of
multiple drug intolerances. A few days prior to the presen-
tation, the patient was started on oral rosuvastatin 10mg
daily for dyslipidemia at the discretion of the primary care
physician. She denied alcohol abuse or a family history of
gastrointestinal disease. Upon presentation to the emergency
room, vital signs were stable and physical examination was
remarkable for epigastric tenderness without guarding or
rigidity and normal bowel sounds. The rectal examination
was unremarkable, and the stool occult blood was negative.
The laboratory data upon presentation to the emergency
room is shown in Table 1. The serum lipase was mildly
elevatedat82U/L. Liverenzymes, including serumbilirubin,
were normal. The CT scan of abdomen, with intravenous
contrast, showed mild edema of pancreatic and peripancre-
atic tissue that was conﬁned to the head and body of the
pancreas, which was consistent with acute pancreatitis. The
abdominal ultrasound showed a normal biliary tree without
choledocholithiasis. Rosuvastatin was held at the time of
admission. She was treated conservatively with bowel rest,
intravenous ﬂuids, and parenteral pain management. She2 Case Reports in Medicine








WBC (cells/cc) 15,000 11,400 4,800–10,800
Hemoglobin (gm/dL) 15.5 14.1 12–16
Glucose (mg/dL) 158 148 70–110
Potassium (mmol/L) 3.1 4.0mmol/L 3.5–5.1
Sodium (mmol/L) 137 138 135–145
Chloride (mmol/L) 101 104 100–110
Bicarbonate (mmol/L) 27 25 22–32
BUN (mg/dL) 14 15 8–23
Creatinine (mg/dL) 0.96 0.89 0.44–1.03
Calcium (mg/dL) 9.3 9.4 8.7–10.2
Amylase (U/L) 67 168 19–132
Lipase (U/L) 82 100 8–56
Triglycerides (mg/dL) 58 64 <150
CEA (ng/mL) N/A 1.3 <3
N/A: not Available.
improved clinically over next 3 days, tolerated regular diet
and was discharged home. Her serum lipase levels trended
down to normal (i.e., 27U/L) during the hospital course.
She was restarted on rosuvastatin at the time of discharge, as
therewasnostrongevidenceofitscorrelationwithAPatthat
time except for one case report. After detailed discussions
regarding the risks and beneﬁts, the patient agreed to restart
rosuvastatin at the time of discharge from the hospital.
Eight weeks later, the patient presented to the emergency
room with vomiting and epigastric pain for 7 days. Her vital
signs were stable, and the physical examination was remark-
able for epigastric tenderness and normal bowel sounds.
The serum amylase and lipase were elevated at 168U/L and
100U/L, respectively. The laboratory data upon presentation
to the emergency room is shown in Table 1. The CT scan
of abdomen, with intravenous contrast, showed mild edema
of the head and body of the pancreas and mild stranding of
the adjacent fat, consistent with acute pancreatitis and there
was no evidence of any pancreatic mass lesion. Magnetic
resonancecholangiopancreatography(MRCP)didnotreveal
biliary sludge or microlithiasis. The serum IgG4 levels were
normal, which ruled out autoimmune pancreatitis. The
patient responded to bowel rest, intravenous ﬂuids, and pain
management. She clinically improved over the next three
days and was able to tolerate regular diet. Serum lipase and
amylase trended down to 22U/L and 44U/L, respectively.
After reviewing case reports of statin-induced pancreatitis
andrulingoutotherdiﬀerentialdiagnoses,itwasdetermined
that rosuvastatin would be stopped at the time of discharge.
The strength of association between rosuvastatin and AP in-
creased during this admission as this could be considered
as a drug rechallenge and all other possible diagnoses were
ruled out. After treatment with rosuvastatin was terminated,
the patient did not have any further episodes of AP and was
completely asymptomatic during the 18-month followup
period. She remained on a strict, fat-free diet and was never
started on any medication for dyslipidemia, as her LDL cho-
lesterol remained at less than 100mg/dL during followup.
3. Discussion
Drug-induced pancreatitis is unusual, but the incidence
may be increasing [12]. There are no distinguishing clinical
features of drug-induced pancreatitis. Diagnosis of drug-
induced AP is based on a high index of clinical suspicion and
detailed drug history. Serum amylase and serum lipase levels
are elevated at least two times the upper normal limit of lab
values in AP. Serum lipase is more speciﬁc than serum amy-
lase in the diagnosis of AP. Serum lipase levels usually decline
slowly over 7–14 days after the onset of AP [13]. Serum
amylase has a shorter half-life than lipase due to rapid renal
clearance [14]. A CT scan of the abdomen, with intravenous
contrast, is the best imaging modality to diagnose, assess
severity, and identify intra-abdominal complications of AP
[15]. Although CT scan of abdomen is usually indicated for
identiﬁcation of complications like pancreatic necrosis or
abscess,itisstillavaluabletoolfordiagnosisifthepatienthas
clinical symptoms of acute pancreatitis and serum amylase
or lipase that are not signiﬁcantly elevated. Management of
drug-induced pancreatitis usually includes intravenous hy-
dration, bowel rest, nutritional support, parenteral pain
management, and withdrawal of the potentially causative
drug. Our patient presented 7 days after the onset of symp-
toms of acute pancreatitis, and serum lipase/amylase usually
starts to trend down over this period of time. However,
there was signiﬁcant evidence of acute pancreatitis on the
CT scan of the abdomen, with intravenous contrast, which
is a highly speciﬁc test for the diagnosis of acute pancreatitis.
Other diagnoses such as biliary disease and malignancy were
ruled out by the ultrasound of the abdomen, MRCP, and
serum tumor markers. The patient responded to supportive
managementwhentherosuvastatinwasstoppedduringboth
episodesofAP.Althoughthepatientwastakingclonidineup-
on presentation, she had not developed AP while taking this
drug for several months before and after her discharge from
the hospital.
Statinsarerecommendedforprimaryandsecondarypre-
vention of coronary artery disease in diabetes mellitus, as
they have been shown to improve mortality in several clin-
ical trials [16]. Intensive drug therapy is recommended to
keep the low-density cholesterol at a low level. Statins are
the most commonly prescribed drugs for the treatment
of dyslipidemia. They are usually well-tolerated drugs and
rarely cause acute pancreatitis. Statin-induced pancreatitis
is reported in medical literature as anecdotal case reports
[7–10]. Pancreatitis that develops during treatment with the
drug, resolves upon discontinuation of the drug, and the fact
that it recurs upon readministration of the drug provides
strong evidence that the drug causes pancreatitis [17]. Pre-
viously reported cases of statin-induced pancreatitis during
the last decade are reported in Table 2.
Singh et al. [9] reported a case of possible rosuvastatin-
induced pancreatitis and described it as a class eﬀect of
statins, as AP occurred during treatment with atorvastatinCase Reports in Medicine 3
Table 2: Previously reported cases of statin-induced pancreatitis.
Author Patient
age/gender Associated drug/s Drug rechallenge Outcome
Belaiche et al. 2000 [4] 63/Male Atorvastatin No Complete recovery
Tysk et al. 2002 [5] 36/Male Fluvastatin Yes: Recurrence Complete recovery
McDonald et al. 2002 [6] 70/Male Simvastatin & Fenoﬁbrate No Fatal
Miltiadous et al. 2003 [7] 60/Male Salicylate & Atorvastatin No Not available
Anagnostopoulos et al. 2003 [8] 56/Male Pravastatin Yes: Recurrence Complete recovery
Singh et al. 2004 [9] 77/Female Atorvastatin & Rosuvastatin Yes: Recurrence with
Rosuvastatin Complete recovery
Antonopoulos et al. 2005 [10] 58/Male Salicylate & Simvastatin No Complete recovery
Tsigrelis and Pitchumoni 2006 [11] 50/Female Pravastatin No Complete recovery
Present case. 2012 67/Female Rosuvastatin Yes: Recurrence Complete recovery
initially and later with rosuvastatin. Anagnostopoulos et al.
[8] described a case of AP that occurred during pravastatin
therapy, and AP recurred ﬁve months later when the patient
resumed taking pravastatin of his own accord. Two case
reports [7, 10] described the occurrence of AP in patients
treated with combined salicylates and statins, which are
commonly prescribed drugs for coronary artery disease.
Badalov and his colleagues [12] categorized the drugs
that cause AP into 4 classes: class I drugs—at least 1 case
report described a recurrence of AP with a rechallenge with
the drug; class II drugs—there is a consistent latency in 75%
ormoreofthereportedcases;classIIIdrugs—therewere2or
more case reports published but no rechallenge or consistent
latency period; class IV drugs—these are similar to class III
drugs, but only one case report was published. Based on this
criterion, rosuvastatin should be considered a class I drug, as
there is at least one case report of rechallenge with the drug.
The Naranjo Adverse Drug Reaction Probability Scale [18]
indicated a probable relationship between the occurrence of
AP and use of rosuvastatin in this patient.
The exact mechanism of statin-induced AP is unknown,
although a few case reports attribute it to drug interaction
through CYP3A4 [19]. All statins except pravastatin are
metabolized by CYP3A4. This could be one of the reasons
that fewer cases of pravastatin-induced AP, as compared to
AP induced by other statins, are reported in the medical
literature [8]. Other potential mechanisms of statin-induced
AP include rhabdomyolysis and myalgias [19]. AP can de-
velop over a period of hours or years after the initiation of
treatment with statins [20]. The period during which the
onset of pancreatitis occurred varied considerably in pre-
viously reported cases of statin-induced AP. AP occurred
during the ﬁrst day of statin treatment in two case reports
[4, 21], while in other cases, it occurred several years after
the initiation of statin therapy. As noted in previous case
reports, there was no consistent latency period for statin-as-
sociated acute pancreatitis. Several case reports of statin-
associatedpancreatitissuggestedthatstatinsmustbestopped
regardless of the latency period. The lack of a consistent
latency period may even suggest possible toxic eﬀects of drug
metabolites on the pancreas [22]. This might be the possible
mechanism in our patient who developed AP few days after
starting rosuvastatin during ﬁrst episode and eight weeks
after restarting rosuvastatin during the second episode.
In conclusion, clinicians should strongly consider statin-
induced pancreatitis, regardless of the duration of statin
therapy, when other likely causes of AP are ruled out. Statins
should be stopped and replaced with other drugs to prevent
further episodes of AP. Statins should be cautiously used for
the treatment of dyslipidemia in view of the potential side
eﬀects related to these drugs.
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